Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

Baber, Usman; Dangas, George; J. Angiolillo, Dominick; J. Cohen, David; K. Sharma, Samin; Nicolas, Johny; Briguori, Carlo; Yu, Jin; Collier, Timothy; Dudek, Dariusz; Džavík, Vladimír; Escaned, Javier; Gil, Robert; A. Gurbel, Paul; W. Hamm, Christian; D. Henry, Timothy; Huber, Kurt; Kastrati, Adnan; Kaul, Upendra; Kornowski, Ran; W. Krucoff, Mitchell; Kunadian, Vijay; O. Marx, Steven; R. Mehta, Shamir; J. Moliterno, David; Magnus Ohman, E.; G. Oldroyd, Keith; Sardella, Gennaro; Sartori, Samantha; Shlofmitz, Richard; Gabríel Steg, Philippe; Weisz, Giora; Witzenbichler, Bernhard; Han, Yaling; Pocock, Stuart; Michael Gibson, C.; Mehran, Roxana

doi:10.1093/eurheartj/ehaa670

Public

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

Published in European Heart Journal • Aug 4, 2020

Authors:

Usman Baber

George Dangas

Dominick J. Angiolillo

Abstract

AIMS: The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary inte...

Subject

Medicine

Ticagrelor

Percutaneous coronary intervention

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!